MediciNova Stock (NASDAQ:MNOV)


OwnershipFinancialsChart

Previous Close

$1.90

52W Range

$1.12 - $2.55

50D Avg

$1.82

200D Avg

$1.49

Market Cap

$95.64M

Avg Vol (3M)

$79.48K

Beta

0.77

Div Yield

-

MNOV Company Profile


MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Dec 08, 2006

Website

MNOV Performance


MNOV Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.00M-$4.04M
Operating Income$-9.90M$-14.63M$-10.22M
Net Income$-8.57M$-14.07M$-10.13M
EBITDA$-9.88M$-14.61M$-10.19M
Basic EPS$-174.76$-0.29$-0.21
Diluted EPS$-174.76$-0.29$-0.21

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CYTCyteir Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
CSBRChampions Oncology, Inc.
ANTXAN2 Therapeutics, Inc.
PHVSPharvaris N.V.
RZLTRezolute, Inc.
PEPGPepGen Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG
ELYMEliem Therapeutics, Inc.